RESUMEN
BACKGROUND AND PURPOSE: The traditional Chinese medicine, diosgenin (Dio), has attracted increasing attention because it possesses various therapeutic effects, including anti-tumor, anti-infective and anti-allergic properties. However, the commercial application of Dio is limited by its extremely low aqueous solubility and inferior bioavailability in vivo. Soluplus, a novel excipient, has great solubilization and capacity of crystallization inhibition. The purpose of this study was to prepare Soluplus-mediated Dio amorphous solid dispersions (ASDs) to improve its solubility, bioavailability and stability. METHODS: The crystallization inhibition studies were firstly carried out to select excipients using a solvent shift method. According to solubility and dissolution results, the preparation methods and the ratios of drug to excipient were further optimized. The interaction between Dio and Soluplus was characterized by differential scanning calorimetry (DSC), fourier transform infrared (FT-IR) spectroscopy, scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and molecular docking. The pharmacokinetic study was conducted to explore the potential of Dio ASDs for oral administration. Furthermore, the long-term stability of Dio ASDs was also investigated. RESULTS: Soluplus was preliminarily selected from various excipients because of its potential to improve solubility and stability. The optimized ASDs significantly improved the aqueous solubility of Dio due to its amorphization and the molecular interactions between Dio and Soluplus, as evidenced by dissolution test in vitro, DSC, FT-IR spectroscopy, SEM, PXRD and molecular docking technique. Furthermore, pharmacokinetic studies in rats revealed that the bioavailability of Dio from ASDs was improved about 5 times. In addition, Dio ASDs were stable when stored at 40°C and 75% humidity for 6 months. CONCLUSION: These results indicated that Dio ASDs, with its high solubility, high bioavailability and high stability, would open a promising way in pharmaceutical applications.
Asunto(s)
Diosgenina/farmacocinética , Desarrollo de Medicamentos , Medicamentos Herbarios Chinos/farmacocinética , Excipientes/farmacocinética , Polietilenglicoles/farmacocinética , Polivinilos/farmacocinética , Administración Oral , Animales , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Cristalografía por Rayos X , Diosgenina/administración & dosificación , Composición de Medicamentos , Estabilidad de Medicamentos , Medicamentos Herbarios Chinos/administración & dosificación , Excipientes/administración & dosificación , Masculino , Medicina Tradicional China , Conformación Molecular , Simulación del Acoplamiento Molecular , Polietilenglicoles/administración & dosificación , Polivinilos/administración & dosificación , Ratas , Ratas Sprague-Dawley , Solubilidad , Espectrometría de Masas en TándemRESUMEN
Atherosclerosis is one of the leading causes of death in patients with cardiovascular diseases worldwide. Although some progress has been made in the treatment of cardiovascular diseases, the morbidity and mortality of cardiovascular diseases still continue to rise. At present, it is an important topic for researchers to develop safe and effective drugs from natural products to prevent and treat cardiovascular diseases. Diosgenin (DSG) is a plant sterol saponin mainly found in natural medicinal plants such as fenugreek seeds and wild yam tubers. More and more studies have reported that DSG has significant pharmacological activities such as anticancer, cardiovascular protection, hypolipidemic, anti-inflammatory, and neuroprotection. Furthermore, diosgenin is also an important basic raw material for the preparation of steroids and contraceptives in the pharmaceutical industry. Numerous preclinical studies have shown that DSG has great potential in the treatment of various cardiovascular diseases in vivo and in vitro, especially in atherosclerosis. This review mainly discusses the effects of DSG on endothelial dysfunction, lipid profile, and macrophage foam cell formation, VSMC viability, thrombosis and inflammation during the formation of atherosclerosis. Also, the mechanism of DSG on atherosclerosis was elaborated in detail. It is noteworthy that newly synthesized DSG derivatives and DSG delivery systems have good antithrombotic activity and pharmacokinetic characteristics.
Asunto(s)
Aterosclerosis/tratamiento farmacológico , Diosgenina/análogos & derivados , Diosgenina/administración & dosificación , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Animales , Aterosclerosis/genética , Aterosclerosis/inmunología , Dioscorea/química , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/inmunología , Humanos , Trigonella/químicaRESUMEN
Diosgenin (Dio) is a steroid sapogenin found in plants such as Dioscorea species, and is recognized as a phytochemical against various disorders as well as a natural precursor of steroidal drugs. The present study used rats fed high-cholesterol (Chol) diets supplemented with or without 0.5% Dio for 6 wk to investigate the effects of dietary Dio on lipid metabolism. Dio supplementation significantly increased serum high-density lipoprotein Chol concentrations and fecal Chol content, and significantly decreased fecal bile acid content compared rats fed a high-Chol diet alone, showing that dietary Dio may facilitate excretion of Chol rather than bile acids. A reduction in the liver triglyceride content and intra-abdominal visceral fat was observed in Dio-supplemented rats. Interestingly, dietary Dio also significantly increased the skeletal muscle-fiber diameter and area in the thigh muscles of the rats. Mouse myoblast-derived C2C12 cells were used to examine whether Dio directly affected skeletal muscle. Dio promoted fusion of myoblasts into multinucleated cells or myotubes. Furthermore, in myotube C2C12 cells, protein levels of phosphorylated AMP-activated protein kinase (AMPK) increased with Dio treatment in a dose-dependent manner. These results indicate that Dio may not only induce myoblast fusion and enhance skeletal muscle as an energy expenditure organ, but may also activate the catabolic pathway via AMPK in skeletal muscle cells. Thus, these effects of Dio on skeletal muscles may contribute to inhibition of visceral fat accumulation.
Asunto(s)
Suplementos Dietéticos , Diosgenina/administración & dosificación , Hipercolesterolemia/terapia , Fibras Musculares Esqueléticas/efectos de los fármacos , Músculo Esquelético/patología , Proteínas Quinasas Activadas por AMP/metabolismo , Animales , Ácidos y Sales Biliares/análisis , Colesterol/análisis , HDL-Colesterol/sangre , Dieta Alta en Grasa , Heces/química , Hipercolesterolemia/sangre , Hipercolesterolemia/etiología , Hipertrofia , Grasa Intraabdominal/metabolismo , Metabolismo de los Lípidos , Hígado/metabolismo , Ratones , Ratas , Muslo/patología , Triglicéridos/análisisRESUMEN
Fenugreek is known since ancient times as a traditional herbal medicine of its multiple beneficial effects. Fenugreek's most studied and employed effect is its hypoglycemic property, but it can also be useful for the treatment of certain thyroid disorders or for the treatment of anorexia. The regulation of glucose homeostasis is a complex mechanism, dependent on the interaction of different types of hormones and neurotransmitters or other compounds. For the study of how diosgenin and fenugreek seeds modify insulin sensitivity, we used a rat insulin resistance model induced by high-fat diet. Diosgenin in three different doses (1mg/bwkg, 10mg/bwkg, and 50 mg/bwkg, respectively) and fenugreek seed (0.2 g/bwkg) were administered orally for 6 weeks. Insulin sensitivity was determined by hyperinsulinemic euglycemic glucose clamp method. Our research group found that although glucose infusion rate was not significantly modified in either group, the increased insulin sensitivity index and high metabolic clearance rate of insulin found in the 1 mg/kg diosgenin and the fenugreek seed treated group suggested an improved peripheral insulin sensitivity. Results from the 10 mg/kg diosgenin group, however, suggest a marked insulin resistance. Fenugreek seed therapy results on the investigated anabolic hormones support the theory that, besides insulin and gastrointestinal peptides, the hypothalamic-hypopituitary axis regulated hormones synchronized action with IGF-1 also play an important role in the maintaining of normal glucose levels. Both diosgenin and fenugreek seeds are capable of interacting with substrates of the above-mentioned regulatory mechanisms, inducing serious hormonal disorders. Moreover, fenugreek seeds showed the ability to reduce the thyroid hormone levels at the periphery and to modify the T4/T3 ratio. It means that in healthy people this effect could be considered a severe side effect; however, in hypothyroidism this effect represents a possibility of alternative natural therapy.
Asunto(s)
Diosgenina/farmacología , Medicina de Hierbas , Resistencia a la Insulina/fisiología , Extractos Vegetales/farmacología , Trigonella/química , Administración Oral , Animales , Dieta Alta en Grasa , Diosgenina/administración & dosificación , Diosgenina/uso terapéutico , Glucosa , Hormona del Crecimiento/análisis , Insulina , Factor I del Crecimiento Similar a la Insulina/análisis , Masculino , Modelos Animales , Extractos Vegetales/uso terapéutico , Plantas Medicinales , Ratas , Ratas Wistar , Hormonas TiroideasRESUMEN
Dioscin, a steroidal saponin isolated from Dioscorea nipponica Makino, has previously been shown to possess antiarthritic effects. However, the underlying mechanism is still elusive. Herein, we investigated the therapeutic effects of dioscin on collagen-induced arthritis (CIA) in DBA/1 mice and related mechanism. Cytokine production in CII-specific immune responses were measured by enzyme-linked immunosorbent assay (ELISA); Th17 cell-related gene expression, including IL-17A, ROR γτ and IL-23p19, were detected by qPCR analysis; Surface marker, T regulatory (Treg) cells and intracellular cytokines (IL-17A and IFN- γ ) were evaluated by flow cytometry. We performed Th17 cell differentiation assay in vitro. Results showed that, in vivo, dioscin treatment significantly reduced the severity of CIA, which was accompanied by decreased Th17 response, but not Th1 and Treg response; dioscin-treated mice also showed lower percentage of CD11b + Gr-1 + neutrophils; In vitro, dioscin treatment suppressed the differentiation of naive CD4 + T cells into Th17 cell and decreased IL-17A production. Collectively, our results indicate that dioscin exerts antiarthritic effects by inhibiting Th17 cell immune response.
Asunto(s)
Artritis/tratamiento farmacológico , Artritis/inmunología , Colágeno/efectos adversos , Dioscorea/química , Diosgenina/análogos & derivados , Fitoterapia , Células Th17/inmunología , Animales , Artritis/inducido químicamente , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Diferenciación Celular/inmunología , Células Cultivadas , Citocinas/metabolismo , Diosgenina/administración & dosificación , Diosgenina/aislamiento & purificación , Diosgenina/farmacología , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones Endogámicos BALB C , Ratones Endogámicos DBARESUMEN
Diosgenin is a phytoestrogen and a constituent of Dioscorea. It has several biological effects, and some of them are anti-inflammatory, antidiabetic, antitumor, and vasodilatory. The present study investigated both the vasorelaxing and antioxidant mechanisms of diosgenin in isolated rat aortic rings. Female rats weighing 200-220 g were subjected to sham or OVX operations at 8 weeks of age. Ovariectomy was performed for menopause induction after anesthesia. Diosgenin (10-9 M-3 × 10-4 M) produced a concentration-dependent relaxation in aortic rings precontracted with phenylephrine (1 µM), exhibiting Emax value of 55.34% ± 7.7% (in endothelium-intact rings) and Emax value of 30.30% ± 5.7% (in endothelium-denuded rings). In the endothelium-intact rings, the vasorelaxing effect of diosgenin was reduced by NG-nitro-l-arginine methyl ester (L-NAME) (100 µM), atropine (1 µM), indomethacin (10 µM), 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) (10 µM), 4-aminopyridine (1 mM), tetraethylammonium (3 mM), glibenclamide (10 µM), apamin (10 µM), and Tiron (1 µM). Diosgenin (10-5 M) inhibited the contractions induced by cumulative addition of phenylephrine (10-9-10-5 M). The 28-days treatment with diosgenin (50 mg/kg, v.o.) did not imply changes in the myeloperoxidase parameter, but increased significantly, levels of glutathione, superoxide dismutase, and nitric oxide, as well as reduced the concentration of malondialdehyde related to lipid peroxidation. Our results suggest that diosgenin induced relaxation in aortic rings via an endothelium-dependent pathway, which involves the EDRF, the opening of potassium channels and antioxidant action.
Asunto(s)
Diosgenina/administración & dosificación , Menopausia/efectos de los fármacos , Fitoestrógenos/administración & dosificación , Extractos Vegetales/administración & dosificación , Vasodilatadores/administración & dosificación , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Dioscorea/química , Diosgenina/química , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Glutatión/metabolismo , Humanos , Técnicas In Vitro , Masculino , Menopausia/metabolismo , Nitritos/metabolismo , Ovariectomía , Estrés Oxidativo/efectos de los fármacos , Fitoestrógenos/química , Extractos Vegetales/química , Canales de Potasio/metabolismo , Ratas , Ratas Wistar , Vasodilatadores/químicaRESUMEN
Fenugreek is a common herb possessing several bioactive components including diosgenin. Here, dietary fenugreek seed flour and diosgenin were evaluated on a model of endothelium-dependent vasorelaxation by abdominal aortas isolated from rats receiving high-fat, high-sugar diet (HFHSD). 60 male Wistar rats were randomized into six groups: (i) negative control getting conventional rat feed regimen; (ii) positive control receiving HFHSD; (iii) a test group fed 2 g/kg bw/day fenugreek seed flour (containing 10 mg/kg bw/day diosgenin) + HFHSD; (iv) three test groups fed 1, 10 and 50 mg/kg bw/day diosgenin + HFHSD. Alimentary treatments were carried out for six weeks. The abdominal aortas were isolated, and 2 mm wide rings were sectioned off and mounted at a resting tension of 10 mN in organ baths containing Krebs solution (36 °C) exposed to 95% O2 and 5% CO2. After 60-min incubation, a norepinephrine concentration-response (E/c) curve was generated to determine their half-maximal effective concentration (EC50) value. After 60-min wash-out, a pre-contraction with norepinephrine EC50 was made, followed by an acetylcholine E/c curve. Plasma glutathione levels, glutathione-handling enzyme activities and blood antioxidant capacities were also determined. HFHSD significantly decreased the dilatory response to acetylcholine and increased plasma glutathione levels and these effects were significantly reversed by fenugreek seed flour, 10 and 50 mg/kg bw/day diosgenin. Both fenugreek and diosgenin treatments prevent HFHSD-induced endothelial dysfunction and redox changes. As fenugreek treatment was more effective at lower acetylcholine concentrations than diosgenin treatments, components of fenugreek other than diosgenin may contribute to the beneficial effects of dietary fenugreek seed flour.
Asunto(s)
Diosgenina/farmacología , Endotelio Vascular/efectos de los fármacos , Síndrome Metabólico/tratamiento farmacológico , Extractos Vegetales/farmacología , Vasodilatación , Animales , Arterias/efectos de los fármacos , Arterias/fisiología , Diosgenina/administración & dosificación , Diosgenina/uso terapéutico , Endotelio Vascular/fisiología , Masculino , Síndrome Metabólico/prevención & control , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Ratas , Ratas Wistar , TrigonellaRESUMEN
In this report, a heat and high-pressure homogenization method was used to prepare dioscin nanostructured lipid carriers, and the formulation of dioscin nanostructured lipid carriers was optimized by central composite design-response surface methodology. In vitro evaluation data showed that the preparation of dioscin nanostructured lipid carriers under optimal process by central composite design-response surface methodology had a spherical shape and homogeneous size distribution, with a particle size of (90.9±0.6) nm, a polydispersity index of (0.253±0.07), Zeta potential of (-45.7±0.5) mV, encapsulation efficiency of (90.2±0.5)%, and the drug loading of (23.30±0.10)%. These results clearly indicate that the preparation of dioscin nanostructured lipid carriers made with the heat and high-pressure homogenization method have very good physical and chemical properties, suitable for therapeutic applications.
Asunto(s)
Diosgenina/análogos & derivados , Portadores de Fármacos/química , Lípidos/química , Nanoestructuras/química , Diosgenina/administración & dosificación , Tamaño de la PartículaRESUMEN
OBJECTIVE: To seek efficient aldose reductase inhibitors (ARIs) with excellent in vitro and in vivo biological activities against rat galactosemic cataract. METHODS: The method was firstly optimized to screen strong ARIs from nonoriented synthetic compounds and natural extracts. Then, diosgenin was assessed on osmotic expansion of primarily cultured lens epithelial cells (LECs) induced by galactose (50 mM). Diosgenin was administered to galactosemic rats by oral (100 and 200 mg/kg) or direct drinking (0.1%) to evaluate its anticataract effects. RESULTS: Diosgenin was found as the strongest ARI with IC50 of 4.59 × 10-6 mol/L. Diosgenin (10 µM) evidently inhibited the formation of tiny vacuoles and upregulation of AR mRNA in LECs. In vivo, diosgenin delayed lens opacification, inhibited the increase of ratio of lens weight to body weight, and decreased AR activity, galactitol level, and AR mRNA expression, especially in the diosgenin drinking (0.1%) group. CONCLUSIONS: Diosgenin was an efficient ARI, which not only significantly decreased the LECs' osmotic expansion in vitro but also markedly delayed progression of rat galactosemic cataract in vivo. Thus, diosgenin rich food can be recommended to diabetic subjects as dietary management to postpone the occurrence of sugar cataract, and diosgenin deserves further investigation for chronic diabetic complications.
Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Catarata/prevención & control , Suplementos Dietéticos , Diosgenina/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Proteínas del Ojo/antagonistas & inhibidores , Cristalino/metabolismo , Aldehído Reductasa/genética , Aldehído Reductasa/aislamiento & purificación , Aldehído Reductasa/metabolismo , Animales , Animales Endogámicos , Catarata/etiología , Catarata/metabolismo , Catarata/patología , Tamaño de la Célula , Supervivencia Celular , Células Cultivadas , Dieta de Carga de Carbohidratos/efectos adversos , Diosgenina/administración & dosificación , Diosgenina/metabolismo , Perros , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/metabolismo , Proteínas del Ojo/genética , Proteínas del Ojo/aislamiento & purificación , Proteínas del Ojo/metabolismo , Galactitol/metabolismo , Galactosa/efectos adversos , Regulación Enzimológica de la Expresión Génica , Cristalino/citología , Cristalino/patología , Masculino , ARN Mensajero/metabolismo , Distribución Aleatoria , Ratas Sprague-Dawley , Vacuolas/patologíaRESUMEN
Creatine monohydrate represents one of the largest sports supplement markets. Enhancing creatine (CRE) stability in aqueous solutions, such as with microencapsulation, represents innovation potential. Ten physically active male volunteers were randomly assigned in a double-blind design to either placebo (PLA) (3-g maltodextrin; n = 5) or microencapsulated CRE (3-g creatine monohydrate; n = 5) conditions. Experimental conditions involved ingestion of the samples in a 70-mL ready-to-drink format. CRE was delivered in a novel microencapsulation matrix material consisting entirely of hydrolyzed milk protein. Three hours after ingestion, plasma creatine concentrations were unchanged during PLA, and averaged â¼45 µM. During CRE, plasma creatine concentration peaked after 30 min at 101.6 ± 14.9 µM (p < 0.05), representing a 2.3-fold increase over PLA. Thereafter, plasma creatine concentration gradually trended downwards but remained significantly elevated (â¼50% above resting levels) 3 hr after ingestion. These results demonstrate that the microencapsulated form of creatine monohydrate reported herein remains bioavailable when delivered in aqueous conditions, and has potential utility in ready-to-drink formulations for creatine supplementation.
Asunto(s)
Creatina/farmacocinética , Diosgenina/farmacocinética , Fitosteroles/farmacocinética , Adulto , Disponibilidad Biológica , Creatina/administración & dosificación , Creatina/sangre , Diosgenina/administración & dosificación , Método Doble Ciego , Composición de Medicamentos , Estabilidad de Medicamentos , Ingestión de Alimentos , Voluntarios Sanos , Humanos , Masculino , Proteínas de la Leche , Fitosteroles/administración & dosificación , Hidrolisados de Proteína , Distribución Aleatoria , SolucionesRESUMEN
Diosgenin (DSG), a well-known steroid sapogenin derived from Dioscorea nipponica Makino and Dioscorea zingiberensis Wright, has a variety of bioactivities. However, it shows low oral bioavailability due to poor aqueous solubility and strong hydrophobicity. The present study aimed to develop DSG nanocrystals to increase the dissolution and then improve the oral bioavailability and biopharmaceutical properties of DSG. DSG nanocrystals were prepared by the media milling method using a combination of pluronic F127 and sodium dodecyl sulfate as surface stabilizers. The physicochemical properties of the optimal DSG nanocrystals were characterized using their particle size distribution, morphology, differential scanning calorimetry, powder X-ray diffraction, Fourier transform infrared spectroscopy data, and solubility and dissolution test results. Pharmacokinetic studies of the DSG coarse suspension and its nanocrystals were performed in rats. The particle size and polydispersity index of DSG nanocrystals were 229.0 ± 3.7 nm and 0.163 ± 0.064, respectively. DSG retained its original crystalline state during the manufacturing process, and its chemical structure was not compromised by the nanonizing process. The dissolution rate of the freeze-dried DSG nanocrystals was significantly improved in comparison with the original DSG. The pharmacokinetic studies showed that the AUC0-72h and C max of DSG nanocrystals increased markedly (p < 0.01) in comparison with the DSG coarse suspension by about 2.55- and 2.01-fold, respectively. The use of optimized nanocrystals is a good and efficient strategy for oral administration of DSG due to the increased dissolution rate and oral bioavailability of DSG nanocrystals.
Asunto(s)
Diosgenina/síntesis química , Diosgenina/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Administración Oral , Animales , Disponibilidad Biológica , Rastreo Diferencial de Calorimetría/métodos , Diosgenina/administración & dosificación , Evaluación Preclínica de Medicamentos/métodos , Liofilización/métodos , Masculino , Nanopartículas/administración & dosificación , Tamaño de la Partícula , Ratas , Ratas Sprague-Dawley , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier/métodos , Difracción de Rayos XRESUMEN
Polyphyllin I (PPI) and formosanin C (FC) were regarded as effective and imperative components isolated from Rhizoma Paridis saponins (RPS) and exhibited strong anti-tumor effects on a variety of cancers. With the wide application of complex mixtures in clinics, synergistic interactions are of vital importance in phytomedicine. Therefore, it is of inherent importance to study whether there is a synergistic anti-tumor effect on PPI and FC from one herb. In this study, the viability was detected by MTT assay. The combination index (CI) analysis was used to assess their synergistic effect. Consequently, there was a synergistic anti-tumor effect between PPI and FC at a ratio of 1:1. The CI value was less than 1.0. Their combination significantly increased their single G1 phase arrest and mitochondria-dependent apoptotic pathway. Meanwhile, PPI and FC reduced the ability of cell migration. In conclusion, polyphyllin I and formosanin C showed a synergistic anti-tumor effect on hepatocarcinoma cells. The findings would provide the foundation for the use of RPS in the future.
Asunto(s)
Diosgenina/análogos & derivados , Neoplasias Hepáticas/patología , Saponinas/administración & dosificación , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Diosgenina/administración & dosificación , Ensayos de Selección de Medicamentos Antitumorales , Sinergismo Farmacológico , Células Hep G2 , HumanosRESUMEN
Previously, we observed that wild yam (Dioscorea villosa) root extract (WYRE) was able to activate GATA3 in human breast cancer cells targeting epigenome. This study aimed to find out if dioscin (DS), a bioactive compound of WYRE, can modulate GATA3 functions and cellular invasion in human breast cancer cells. MCF-7 and MDA-MB-231 cells were treated in the absence/presence of various concentrations of DS and subjected to gene analysis by RT-qPCR, immunoblotting, and immunocytochemistry. We determined the ability of MDA-MB-231 cells to migrate into wound area and examined the effects of DS on cellular invasion using invasion assay. DS reduced cell viability of both cell lines in a concentration and time-dependent manner. GATA3 expression was enhanced by DS (5.76 µM) in MDA-MB-231 cells. DS (5.76 µM)-treated MDA-MB-231 cells exhibited the morphological characteristic of epithelial-like cells; mRNA expression of DNMT3A, TET2, TET3, ZFPM2 and E-cad were increased while TET1, VIM and MMP9 were decreased. Cellular invasion of MDA-MB-231 was reduced by 65 ± 5% in the presence of 5.76 µM DS. Our data suggested that DS-mediated pathway could promote GATA3 expression at transcription and translation levels. We propose that DS has potential to be used as an anti-invasive agent in breast cancer.
Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Dioscorea/química , Diosgenina/análogos & derivados , Extractos Vegetales/administración & dosificación , Raíces de Plantas/química , Antineoplásicos/administración & dosificación , Neoplasias de la Mama/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Diosgenina/administración & dosificación , Relación Dosis-Respuesta a Droga , Humanos , Células MCF-7 , Invasividad Neoplásica , Fitosteroles/administración & dosificación , Saponinas/administración & dosificación , Resultado del TratamientoRESUMEN
OBJECTIVE: To observe the preventive and therapeutic effects of diosgenin on retinoic acid-induced osteoporosis in rats. METHODS: A total 50 Sprague-Dawley rats were randomly divided into 5 groups: control group, model group (osteoporosis rats), low (10 mg kg(-1)), middle (30 mg kg(-1)), and high-dose diosgenin (90 mg kg(-1))-treated groups. The osteoporosis rats model was induced by retinoic acid. The BMD and physical parameters of femoral including length, wet weight, and dry weight in each group were measured. The hematoxylin-eosin staining was used for bone histomorphology analysis. Besides, the bone calcium (Ca) and phosphorus (P) contents were measured. In order to detect the biochemical index in different treatment groups, the serum tartrate-resistant acid phosphatase (TRAP), alkaline phosphatase (ALP), estradiol, and osteocalcin were compared among different groups. RESULTS: The osteoporosis rat model was successfully induced by retinoic acid. Compared with the model group, the lessening of femoral length and weight and the loss of BMD were significantly improved in diosgenin groups. Both contents of Ca and P were much more increased when induced by retinoic acid (p < 0.05). The estradiol and osteocalcin levels in the middle and high-dose treatment groups were significantly higher than that of the model group, while the ALP and TRAP levels were much lower than the model group (p < 0.05). CONCLUSION: Diosgenin can prevent the loss of bone in experimental rats. The mechanism may be that it improves the level of estrogenic hormone of estradiol and inhibits the high bone turnover.
Asunto(s)
Diosgenina/uso terapéutico , Osteoporosis/tratamiento farmacológico , Tretinoina/efectos adversos , Animales , Densidad Ósea/efectos de los fármacos , Diosgenina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Osteoporosis/inducido químicamente , Ratas , Ratas Sprague-DawleyRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Among the 49 species of the genus Dioscorea distributed in China, Dioscorea nipponica Makino (DN), Dioscorea panthaica Prain et Burkill (DP), and Dioscorea zingiberensis C. H. Wright (DZ) possess more or less similar traditional therapeutic actions, such as activating blood, relieving pain, and dispersing swelling; they have been used as folk medicine in China since 1950s. The modern pharmaceutical industry has developed these three species as herbal medicines that have been used for decades for treating cardiovascular diseases. However, there is no available information in the literature explaining how their chemical components are converted and interrelated in vivo to support their efficacies. The present study aimed to a) compare the metabolic profiles of saponins from DN, DP and DZ, which are considered to be their bioactive components, and b) to compare the changes in sustained levels of metabolites from rat biosamples. MATERIAL AND METHODS: Total saponins (TS) from each of the three species, and four individual saponins, namely protodioscin (PD), pseudoprotodioscin (PSD), dioscin (DC) and diosgenin (DG), were given to rats by oral administration. Chemical profiles of the rats' plasma, urine and feces were monitored 1-36 h. A UPLC-QTOF-MS based method was performed to identify the absorbed constituents and their metabolic products in rat biosamples (i.e., blood, urine, and feces); the ratio of peak area of major saponins to that of internal standard was calculated and plotted versus time to characterize the sustained levels of saponins in biosamples. RESULTS: Totally 10 saponin-related compounds were detected in rat plasma, 10 in rat urine and 18 in rat feces. The results indicated that formation of diosgenin by desugarization was the main pathway by which steroidal glycosides were metabolized. Other types of bio-transformation were found among glycosides and aglycones, such as ring cyclization through loss of 26-O-glucosyl, substitution of ß-D-glucopyranosyl for α-L-rhamnopyrannosyl, hydrogenation of diosgenin at 5(6)-double bond, and hydration of 20(22)-double bond. Generally, the metabolic profiles of DN and DP were shown to be quite similar, but different from that of DZ. However, some particular similarities and connections were found among these three TS. Diosgenin was one of the main metabolites commonly found in plasma and feces (excluding urine), from all groups receiving different TS, as well as individual saponins; this is likely to be one of the bioactive constituents playing an essential role in cardioprotective efficacy. Furostane-type saponins in TS of DN, DP or DZ, such as PD, protogracillin, parvifloside, protodeltonin and protobioside, showed fast absorption into blood (<1h), but were maintained for a relatively short period (mostly<8h), while the spirostane-type saponin and sapogenin (DC and DG, respectively), were absorbed into circulation more slowly (>1h), but increased gradually and lasted longer (>36h). These two patterns suggest that the therapeutic effect of these Dioscorea saponins is achieved through a complex, multi-step process over time. In addition, it appears that PD, PSD, and DC contained in DN and DP were transformed into certain glycosides originally found in DZ but not in DN or DP (protodeltonin, deltonin, trillin, and progenin II), which might indicate another linkage among these three species. CONCLUSION: These similarities and connections described above constitute evidence supporting similarity in efficacy of these three herbs from the perspective of metabolism. The UPLC-QTOF-MS based method is accurate and efficient for analyzing metabolic changes in rat biosamples over time.
Asunto(s)
Dioscorea/química , Medicamentos Herbarios Chinos/farmacocinética , Saponinas/farmacocinética , Administración Oral , Animales , Cromatografía Líquida de Alta Presión/métodos , Diosgenina/administración & dosificación , Diosgenina/análogos & derivados , Diosgenina/farmacocinética , Diosgenina/farmacología , Medicamentos Herbarios Chinos/administración & dosificación , Heces/química , Masculino , Espectrometría de Masas/métodos , Ratas , Ratas Sprague-Dawley , Saponinas/administración & dosificación , Saponinas/análisis , Saponinas/sangre , Saponinas/orinaRESUMEN
Diabetes mellitus is associated with significant morbidity and mortality that contributes to pathogenesis of cardiovascular diseases. Diosgenin, a naturally occurring aglycone, is present abundantly in fenugreek. The steroidal saponin is being used as a traditional medicine for diabetes. The present study has investigated the effects of diosgenin on lipid profile in the heart and brain, mRNA expression, and hepatic HMG-CoA reductase (HMGR) activity of streptozotocin-induced diabetic rats. In our study, diosgenin was administered (40 mg/kg b.w.) orally for 45 days to control animals and experimentally induced diabetic rats. The effects of diosgenin on glucose, plasma insulin, cholesterol, triglycerides, free fatty acids, and phospholipids (PLs) in the heart and brain were studied. The levels of glucose, cholesterol, triglycerides, free fatty acids, PLs, and HMGR activity were increased significantly (P < 0.05) whereas plasma insulin level was decreased in diabetic rats. Administration of diosgenin to diabetic rats significantly reduced blood glucose, cholesterol, triglycerides, free fatty acids, PLs levels, and also HMGR activity. In addition, the plasma insulin level was increased in diosgenin-treated diabetic rats. The above findings were correlated with histological observations of the heart and brain. The results showed that administration of diosgenin remarkably increased plasma insulin level with absolute reduction of blood glucose, lipid profile, and HMGR level when compared to diabetic control rats. The results have suggested that diosgenin prevents hypercholesterolemia and hepatosteatosis by modulation of enzymatic expression that is associated with cholesterol metabolism.
Asunto(s)
Encéfalo/metabolismo , Diabetes Mellitus Experimental/tratamiento farmacológico , Diosgenina/farmacología , Hidroximetilglutaril-CoA Reductasas/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Miocardio/metabolismo , Animales , Glucemia/metabolismo , Encéfalo/efectos de los fármacos , Colesterol/sangre , Diabetes Mellitus Experimental/metabolismo , Diosgenina/administración & dosificación , Diosgenina/uso terapéutico , Ácidos Grasos/sangre , Corazón/efectos de los fármacos , Hidroximetilglutaril-CoA Reductasas/genética , Insulina/sangre , Masculino , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Triglicéridos/sangreRESUMEN
The aim of this study was to evaluate effect of diosgenin (DG) on rats that had osteoporosis-like features induced by ovariectomy (OVX). Seventy-two six-month-old female Wistar rats were subjected to either ovariectomy (n = 60) or Sham operation (SHAM group, n = 12). Beginning at one week post-ovariectomy, the OVX rats were treated with vehicle (OVX group, n = 12), estradiol valerate (EV group, n = 12), or DG at three doses (DG-L, -M, -H group, n = 12, respectively). After a 12-week treatment, administration of EV or DG-H inhibited OVX-induced weight gain, and administration of EV or DG-H or DG-M had a significantly uterotrophic effect. Bone mineral density (BMD) and indices of bone histomorphometry of tibia were measured. Levels of protein and mRNA expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) in tibia were evaluated by immunohistochemistry and in situ hybridization. Our results show that DG at a high dose (DG-H) had a significant anti-osteoporotic effect compared to OVX control. DG-H treatment down-regulated expression of RANKL and up-regulated expression of OPG significantly in tibia from OVX rats compared to control, and thus lowered the RANKL/OPG ratio. This suggests that the anti-osteoporotic effect of DG might be associated with modulating the RANKL/OPG ratio and DG had potential to be developed as alternative therapeutic agents of osteoporosis induced by postmenopause.
Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Densidad Ósea/efectos de los fármacos , Diosgenina/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Osteoprotegerina/biosíntesis , Ligando RANK/biosíntesis , Animales , Peso Corporal/efectos de los fármacos , Conservadores de la Densidad Ósea/administración & dosificación , Diosgenina/administración & dosificación , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Estradiol/análogos & derivados , Estradiol/uso terapéutico , Terapia de Reemplazo de Estrógeno , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Tamaño de los Órganos/efectos de los fármacos , Osteoprotegerina/genética , Ovariectomía/efectos adversos , Ligando RANK/genética , Ratas , Ratas Wistar , Tibia/metabolismo , Tibia/patología , Útero/efectos de los fármacos , Útero/patologíaRESUMEN
This study was performed to compare the effects of creatine supplementation (CR) before vs. after supervised resistance training (RT) in healthy older adults. Participants were randomized to one of two groups: CR-Before (0.1gâ¢kg(-1) creatine before + 0.1gâ¢kg(-1) placebo [rice flour] after RT, n = 11) or CR-After (placebo before + creatine after RT, n = 11). Resistance training (RT) was performed 3 days/week, on nonconsecutive days, for 12 weeks. Prior to and following the study, measures were taken for body composition, maximum strength, muscle protein catabolism, and kidney function. Over the 12-week training period, both groups experienced a significant increase in whole-body lean tissue mass, limb muscle thickness, and upper and lower body strength and a decrease in muscle protein catabolism (p < 0.001), with no differences between groups. There was no change in kidney function over time. Changes in muscle mass or strength are similar when creatine is ingested before or after supervised resistance training in older adults.
Asunto(s)
Creatina/administración & dosificación , Diosgenina/administración & dosificación , Voluntarios Sanos , Fuerza Muscular/efectos de los fármacos , Esfuerzo Físico/efectos de los fármacos , Fitosteroles/administración & dosificación , Entrenamiento de Fuerza/métodos , Suplementos Dietéticos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Diosgenin (Dio), a major active component of steroidal sapogenin of the traditional Chinese herb Dioscorea zingiberensis C.H.Wright, shows various activities including anti-inflammatory, anti-thrombotic activities, anti-cancer properties etc. In the present study, we found that diosgenin significantly suppressed the phosphorylation of lung NF-κB p50/p65 and MAPK/p38 in lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice, when given orally at doses of 0.1, 1.0 and 10mg/kg 1h prior to LPS challenge (30 mg/kg, intravenous injection). Moreover, diosgenin attenuated the lung histopathological changes such as pulmonary edema, coagulation and infiltration of inflammatory cells. In addition, diosgenin significantly decreased the lung wet to dry weight (W/D) ratio and nitrite/nitrate content at three doses, and also markedly inhibited LPS-induced body temperature decrease and nitrite/nitrate elevation in plasma. Besides, diosgenin could significantly suppress activation of NF-κB p65/p50, p38 and expression of inducible nitric oxide synthase (iNOS) in LPS-induced THP-1 cells. Our findings indicate the potential application of diosgenin for ALI treatment.
Asunto(s)
Antiinflamatorios/administración & dosificación , Diosgenina/administración & dosificación , Pulmón/efectos de los fármacos , Monocitos/efectos de los fármacos , Factor de Transcripción ReIA/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo , Lesión Pulmonar Aguda , Animales , Línea Celular , Movimiento Celular/efectos de los fármacos , Dioscorea/inmunología , Modelos Animales de Enfermedad , Regulación hacia Abajo , Humanos , Lipopolisacáridos/inmunología , Pulmón/patología , Masculino , Medicina Tradicional China , Ratones , Ratones Endogámicos ICR , Monocitos/inmunología , Transducción de Señal/efectos de los fármacos , Factor de Transcripción ReIA/genética , Proteínas Quinasas p38 Activadas por Mitógenos/genéticaRESUMEN
This experiment established the ovariectomized (OVX) rat model of postmenopausal osteoporosis and examined the effect of the oral administration of different dosages of dioscorea, red mold dioscorea (RMD), and soy isoflavones on bone mineral density (BMD). Three months after osteoporosis had been induced and 4 weeks after feeding had begun, the tibia and femur BMD of OVX rats administered RMD showed significant increases compared with that of all other groups of OVX rats. Closer examination using microcomputed tomography also revealed that the RMD-administered rats had denser trabecular bone volume and a higher trabecular number compared to all other rat groups. Reconstructed 3D imaging indicated increases in cancellous bone mineral content, cancellous bone mineral density, and cortical bone mineral content of the proximal tibia in OVX rats. These findings indicate that administration of monacolin K and phytoestrogen diosgenin could prevent bone loss induced by estrogen deficiency.